Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis

被引:100
作者
Granados, Andrea [1 ]
Chan, Christine L. [2 ]
Ode, Katie Larson [3 ]
Moheet, Amir [4 ]
Moran, Antoinette [5 ]
Holl, Reinhard [6 ]
机构
[1] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA
[2] Univ Colorado, Barbara Davis Ctr Childhood Diabet, Childrens Hosp Colorado, Aurora, CO USA
[3] Univ Iowa, Dept Pediat, Fraternal Order Eagles Diabet Res Ctr, Stead Family Childrens Hosp, Iowa City, IA 52242 USA
[4] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA
[5] Univ Minnesota, Div Pediat Endocrinol, Minneapolis, MN USA
[6] Univ Ulm, Ulm, Germany
关键词
Cystic fibrosis; Cystic fibrosis related diabetes; Pathophysiology; Screening; Diagnosis; ORAL GLUCOSE-TOLERANCE; INSULIN-SECRETION; MICROVASCULAR COMPLICATIONS; CLINICAL STATUS; CHILDREN; MELLITUS; EPIDEMIOLOGY; RESISTANCE; ABNORMALITIES; ASSOCIATION;
D O I
10.1016/j.jcf.2019.08.016
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Cystic fibrosis related diabetes (CFRD) is a distinct form of diabetes that is associated with significantly increased morbidity and mortality in the CF population. The primary etiology is relative insulin insufficiency secondary to destruction of pancreatic islets, and to other factors that affect the function of the remaining beta cells. The prevalence of CFRD increases markedly with age and more than half of CF adults develop the disease. As the initial presentation of CFRD may be clinically silent, annual screening is recommended starting at least by the age of 10 with an oral glucose tolerance test (OGTT). The importance of an early diagnosis is based on the association of diabetes and abnormal glucose tolerance with worse health outcomes in patients with CF, and evidence that early treatment of diabetes improves prognosis. This review presents a concise overview of the current understanding of CFRD pathogenesis, natural history, screening and diagnosis. (C) 2019 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.
引用
收藏
页码:S3 / S9
页数:7
相关论文
共 79 条
[1]   Genetic determinants and epidemiology of cystic fibrosis-related diabetes - Results from a British cohort of children and adults [J].
Adler, Amanda I. ;
Shine, Brian S. F. ;
Chamnan, Parinya ;
Haworth, Charles S. ;
Bilton, Diana .
DIABETES CARE, 2008, 31 (09) :1789-1794
[3]  
[Anonymous], 2019, STAND MED CAR DIAB 2, P42
[4]  
Antoinette Moran, 2018, PEDIAT DIABETES, V27, P64
[5]   LONGITUDINAL EVALUATION OF GLUCOSE-TOLERANCE AND INSULIN-SECRETION IN NONDIABETIC CHILDREN AND ADOLESCENTS WITH CYSTIC-FIBROSIS - RESULTS OF A 2-YEAR FOLLOW-UP [J].
ARRIGO, T ;
CUCINOTTA, D ;
NIBALI, SC ;
DICESARE, E ;
DIBENEDETTO, A ;
MAGAZZU, G ;
DELUCA, F .
ACTA PAEDIATRICA, 1993, 82 (03) :249-253
[6]   Age- and Sex-Dependent Distribution of OGTT-Related Variables in a Population of Cystic Fibrosis Patients [J].
Battezzati, Alberto ;
Bedogni, Giorgio ;
Zazzeron, Laura ;
Mari, Andrea ;
Battezzati, Pier Maria ;
Alicandro, Gianfranco ;
Bertoli, Simona ;
Colombo, Carla .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (08) :2963-2971
[7]   Genetic Modifiers of Cystic Fibrosis-Related Diabetes [J].
Blackman, Scott M. ;
Commander, Clayton W. ;
Watson, Christopher ;
Arcara, Kristin M. ;
Strug, Lisa J. ;
Stonebraker, Jaclyn R. ;
Wright, Fred A. ;
Rommens, Johanna M. ;
Sun, Lei ;
Pace, Rhonda G. ;
Norris, Sarah A. ;
Durie, Peter R. ;
Drumm, Mitchell L. ;
Knowles, Michael R. ;
Cutting, Garry R. .
DIABETES, 2013, 62 (10) :3627-3635
[8]  
Blacknial E, 2009, DIABETOLOGIA, V52, P1
[9]   Structural abnormalities in islets from very young children with cystic fibrosis may contribute to cystic fibrosis-related diabetes [J].
Bogdani, Marika ;
Blackman, Scott M. ;
Ridaura, Cecilia ;
Belloc, Jean-Pierre ;
Powers, Alvin C. ;
Aguilar-Bryan, Lydia .
SCIENTIFIC REPORTS, 2017, 7
[10]   Glycated hemoglobin cannot yet be proposed as a screening tool for cystic fibrosis related diabetes [J].
Boudreau, Valerie ;
Coriati, Adele ;
Desjardins, Katherine ;
Rabasa-Lhoret, Remi .
JOURNAL OF CYSTIC FIBROSIS, 2016, 15 (02) :258-260